Eden Biodesign to Manufacture Therapeutic Candidate for Borean Pharma
Eden Biodesign Limited, (Liverpool, UK, www.edenbiodesign.com), and Borean Pharma (Aarhus, Denmark, www.boreanpharma.com), have signed an agreement under which Eden will manufacture MBP-DC-SIGN, a novel therapeutic candidate for the treatment of a range of cancers, for Borean to use in preclinical studies.
Eden Biodesign Limited, (Liverpool, UK, www.edenbiodesign.com), and Borean Pharma (Aarhus, Denmark, www.boreanpharma.com), have signed an agreement under which Eden will manufacture MBP-DC-SIGN, a novel therapeutic candidate for the treatment of a range of cancers, for Borean to use in preclinical studies. The project is expected to be completed early in 2008.
MBP-DC-SIGN is a Borean product based on its mannose-binding protein platform, which delivers a series of highly potent therapeutics for the treatment of cancers. It is the only scaffold that can induce complement-induced lysis.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
